Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | GERN |
---|---|---|
09:32 ET | 51116 | 4.445 |
09:34 ET | 59246 | 4.4 |
09:36 ET | 31952 | 4.38 |
09:38 ET | 5645 | 4.395 |
09:39 ET | 1450 | 4.395 |
09:41 ET | 33264 | 4.395 |
09:43 ET | 253402 | 4.41 |
09:45 ET | 38307 | 4.4 |
09:48 ET | 13688 | 4.395 |
09:50 ET | 13493 | 4.395 |
09:52 ET | 16462 | 4.375 |
09:54 ET | 157441 | 4.36 |
09:56 ET | 18920 | 4.37 |
09:57 ET | 19772 | 4.36 |
09:59 ET | 3876 | 4.3651 |
10:01 ET | 21667 | 4.37 |
10:03 ET | 8094 | 4.375 |
10:06 ET | 7743 | 4.37 |
10:08 ET | 41116 | 4.375 |
10:10 ET | 39681 | 4.36 |
10:12 ET | 73587 | 4.335 |
10:14 ET | 37561 | 4.34 |
10:15 ET | 19585 | 4.33 |
10:17 ET | 3057 | 4.335 |
10:19 ET | 670016 | 4.35 |
10:21 ET | 25282 | 4.3856 |
10:24 ET | 18189 | 4.38 |
10:26 ET | 12993 | 4.395 |
10:28 ET | 19251 | 4.395 |
10:30 ET | 4981 | 4.385 |
10:32 ET | 16583 | 4.385 |
10:33 ET | 17792 | 4.385 |
10:35 ET | 16059 | 4.385 |
10:37 ET | 8262 | 4.385 |
10:39 ET | 7340 | 4.4 |
10:42 ET | 4031 | 4.405 |
10:44 ET | 25172 | 4.415 |
10:46 ET | 152999 | 4.41 |
10:48 ET | 24206 | 4.43 |
10:50 ET | 14300 | 4.435 |
10:51 ET | 2788 | 4.43 |
10:53 ET | 10660 | 4.435 |
10:55 ET | 72091 | 4.42 |
10:57 ET | 25475 | 4.415 |
11:00 ET | 17483 | 4.41 |
11:02 ET | 42014 | 4.42 |
11:04 ET | 600 | 4.425 |
11:06 ET | 14733 | 4.42 |
11:08 ET | 15158 | 4.43 |
11:09 ET | 14586 | 4.43 |
11:11 ET | 10590 | 4.44 |
11:13 ET | 10900 | 4.44 |
11:15 ET | 14667 | 4.45 |
11:18 ET | 33158 | 4.45 |
11:20 ET | 14920 | 4.44 |
11:22 ET | 600 | 4.44 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Geron Corp | 2.7B | -12.4x | --- |
Immunitybio Inc | 2.7B | -4.2x | --- |
Iovance Biotherapeutics Inc | 2.8B | -5.7x | --- |
Vera Therapeutics Inc | 2.5B | -20.3x | --- |
CG Oncology Inc | 2.5B | -32.5x | --- |
Edgewise Therapeutics Inc | 2.4B | -17.1x | --- |
Geron Corporation is a late-stage clinical biopharmaceutical company developing investigational first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies. The Company is engaged in the development of therapeutic products for oncology. Its lead indication for imetelstat is in Low or Intermediate-1 risk myelodysplastic syndromes. It is developing imetelstat for the treatment of several myeloid hematologic malignancies, including a Phase 3 clinical trial, named IMpactMF, in relapsed/refractory myelofibrosis (MF) with overall survival as the primary endpoint, that is enrolling patients. It is also conducting a Phase 1 combination therapy clinical trial, named IMproveMF, in first-line Intermediate-1, Intermediate-2 or High-Risk myelofibrosis, or frontline MF, that is enrolling patients and imetelstat is being studied in an investigator-led Phase 2 clinical trial, named IMpress, in Intermediate-2 or High-Risk myelodysplastic syndromes and acute myeloid leukemia.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.7B |
---|---|
Revenue (TTM) | $1.4M |
Shares Outstanding | 602.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.50 |
EPS | $-0.36 |
Book Value | $0.46 |
P/E Ratio | -12.4x |
Price/Sales (TTM) | 1,944.9 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -16,559.94% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.